Engineered Gut Bacteria for Phenylalanine Breakdown in PKU
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperphenylalaninemia, such as phenylketonuria (PKU), are costly, difficult to adhere to, and often cause side effects, with a significant need for effective, reliable, and long-term management of phenylalanine levels.
Innovation Solution
Genetically engineered bacteria expressing phenylalanine ammonia lyase (PAL) and optionally L-amino acid deaminase, equipped with an inducible promoter and phenylalanine transporter, are introduced into the gut to metabolize phenylalanine into non-toxic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein-restricted diet is used to treat PKU, then blood phenylalanine levels are reduced, but patient compliance becomes difficult and quality of life deteriorates
Solution Approach 1:
The patent uses engineered probiotic bacteria as an intermediary agent that resides in the gut and actively metabolizes excess phenylalanine. This mediator converts the harmful substance (phenylalanine) into non-toxic compounds, thereby treating PKU without requiring patients to adhere to strict dietary restrictions, thus resolving the contradiction between treatment effectiveness and ease of operation
Solution Approach 2:
The engineered bacteria perform self-service by autonomously metabolizing phenylalanine in the gut through their internal PAL enzyme system. The bacteria take up phenylalanine via their transporters, convert it to non-toxic metabolites through PAL activity, and excrete the products, thereby providing continuous treatment without requiring active patient compliance with dietary restrictions
2Reliability
If oral PAL enzyme therapy is administered, then phenylalanine metabolism is improved, but sufficient enzyme amounts at reasonable cost are not available
Solution Approach 1:
The patent employs live probiotic bacteria as a cost-effective alternative to purified enzyme therapy. These bacteria can be produced at scale using standard fermentation processes, are stable in oral formulations, and provide sustained enzyme activity through their metabolic machinery, offering a more economical solution than purified PAL enzyme preparations
Solution Approach 2:
The engineered probiotic bacteria serve multiple functions: they act as living enzyme factories producing PAL activity, provide phenylalanine uptake capacity through their transporters, offer gut colonization stability, and deliver continuous metabolic activity. This multi-functionality makes them superior to simple enzyme supplementation, addressing both effectiveness and manufacturability
3Reliability
If PEG-PAL injectable treatment is used, then phenylalanine levels are reduced, but injection site reactions and antibody formation occur
Solution Approach 1:
The patent replaces the mechanical injection delivery system with an oral administration route. The engineered probiotics are delivered via the gastrointestinal tract, avoiding needle injections entirely. This substitution eliminates injection site reactions and reduces immunogenicity while maintaining therapeutic effectiveness through the bacteria's metabolic activity in the gut
Solution Approach 2:
The live probiotic bacteria serve as a biocompatible intermediary that delivers phenylalanine metabolic activity without the immunogenicity of purified recombinant proteins. The bacteria's cellular context provides a more natural, less immunogenic delivery system compared to PEG-PAL injections, reducing harmful immune responses while maintaining treatment effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered bacteria effectively reduce blood phenylalanine levels, providing a stable and long-term treatment option with minimal side effects, potentially reducing the neurological and physical symptoms associated with PKU.
Implementation Method 1
one or more gene(s) encoding a phenylalanine transporter capable of transporting phenylalanine into bacterial cells
Implementation Method 2
one or more gene(s) encoding a phenylalanine ammonia lyase (PAL) capable of metabolizing phenylalanine into non-toxic compounds
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.